Affordable Access

Access to the full text

Assessing the Impact of Cyclosporin A on Lentiviral Transduction and Preservation of Human Hematopoietic Stem Cells in Clinically Relevant Ex Vivo Gene Therapy Settings

Authors
  • Petrillo, Carolina1, 2
  • Calabria, Andrea1
  • Piras, Francesco1, 2
  • Capotondo, Alessia1
  • Spinozzi, Giulio1
  • Cuccovillo, Ivan1
  • Benedicenti, Fabrizio1
  • Naldini, Luigi1, 2
  • Montini, Eugenio1
  • Biffi, Alessandra1, 3, 4
  • Gentner, Bernhard1
  • Kajaste-Rudnitski, Anna1
  • 1 San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS Ospedale San Raffaele, Milan, Italy
  • 2 Vita-Salute San Raffaele University, School of Medicine, Milan, Italy
  • 3 Gene Therapy Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts
  • 4 Program for Gene Therapy in Rare Diseases, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts.
Type
Published Article
Journal
Human Gene Therapy
Publisher
Mary Ann Liebert
Publication Date
Sep 01, 2019
Volume
30
Issue
9
Pages
1133–1146
Identifiers
DOI: 10.1089/hum.2019.016
PMID: 31037976
PMCID: PMC6761585
Source
PubMed Central
Keywords
License
Green

Abstract

Improving hematopoietic stem and progenitor cell (HSPC) permissiveness to lentiviral vector (LV) transduction without compromising their biological properties remains critical for broad-range implementation of gene therapy as a treatment option for several inherited diseases. This study demonstrates that the use of one-hit ex vivo LV transduction protocols based on either cyclosporin A (CsA) or rapamycin enable as efficient gene transfer as the current two-hit clinical standard into bone marrow–derived CD34+ cells while better preserving their engraftment capacity in vivo . CsA was additive with another enhancer of transduction, prostaglandin E2, suggesting that tailored enhancer combinations may be applied to overcome multiple blocks to transduction simultaneously in HSPC. Interestingly, besides enhancing LV transduction, CsA also significantly reduced HSPC proliferation, preserving the quiescent G0 fraction and the more primitive multipotent progenitors, thereby yielding the highest engraftment levels in vivo . Importantly, no alterations in the vector integration profiles could be detected between CsA and control transduced HSPC. Overall, the present findings contribute to the development of more efficient and sustainable LV gene therapy protocols, underscoring the benefits of scaling down required vector doses, as well as shortening the HSPC ex vivo culture time.

Report this publication

Statistics

Seen <100 times